Treatment of hemangiomas of infancy

Authors

  • Victoria R. Barrio,

    1. Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI
    Search for more papers by this author
  • Beth A. Drolet

    Corresponding author
    1. Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI
      Address correspondence and reprint requests to: Beth A. Drolet, MD, MCW Clinics at Froedtert, 9200 West Wisconsin Ave, Milwaukee, WI, 53226, or email: drolet@mcw.edu.
    Search for more papers by this author

Address correspondence and reprint requests to: Beth A. Drolet, MD, MCW Clinics at Froedtert, 9200 West Wisconsin Ave, Milwaukee, WI, 53226, or email: drolet@mcw.edu.

Abstract

ABSTRACT:  Hemangiomas of infancy are the most common tumors of childhood. They are clinically heterogeneous and as such require individualized treatment plans. Although there are no Food and Drug Administration (FDA)-approved agents for treatment of hemangiomas of infancy, there are many widely used therapeutic options available. This review highlights the treatments currently in use and the factors that direct treatment.

Ancillary